Septerna, Inc. Common Stock (SEPN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Septerna, Inc. Common Stock (SEPN) has a cash flow conversion efficiency ratio of 0.434x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($168.81 Million) by net assets ($388.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SEPN defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Septerna, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Septerna, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Septerna, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Septerna, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
First Tractor Co Ltd
SHG:601038
|
-0.009x |
|
Huafon Microfibre Shanghai Co
SHE:300180
|
0.029x |
|
GuoChuang Software Co Ltd
SHE:300520
|
0.007x |
|
Edelweiss Financial Services Limited
NSE:EDELWEISS
|
-0.125x |
|
Xinjiang Tecon Animal Husbandry Bio-Technology Co Ltd
SHE:002100
|
0.087x |
|
Tessenderlo
BR:TESB
|
0.057x |
|
Luolai Home Textile Co Ltd
SHE:002293
|
0.040x |
|
Blackbaud Inc
NASDAQ:BLKB
|
0.682x |
Annual Cash Flow Conversion Efficiency for Septerna, Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Septerna, Inc. Common Stock from 2022 to 2024. For the full company profile with market capitalisation and key ratios, see Septerna, Inc. Common Stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $420.05 Million | $-67.47 Million | -0.161x | -115.92% |
| 2023-12-31 | $-38.37 Million | $-38.72 Million | 1.009x | +91.40% |
| 2022-12-31 | $-44.20 Million | $-23.30 Million | 0.527x | -- |
About Septerna, Inc. Common Stock
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 … Read more